A Nova radio host has admitted live on-air to taking a weight loss drug popular with celebrities that costs an arm and a leg ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

"It's frankly scary what people will put up with when they're losing weight" Dr Michael Crotty on the rollout of Mounjaro ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

U.S. lawmakers propose banning DeepSeek's app on government devices over security concerns, similar to the TikTok ban, citing links to China's government. Roblox faces a significant drop after ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

After Kelly Clarkson debuted her striking weight loss in 2023, many suspected her success was due to Ozempic. While the ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's ...

Mounjaro and Zepbound. The stock was headed for its biggest one-day drop since the 9.1% selloff on March 15, 2021. Despite the stock's reaction, Citi Research analyst Geoff Meacham said the ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...